Insomnia drug market set to take major hit to 2016, with only partial recovery by 2023

17 February 2015

The insomnia drug market is set to fall rapidly by 2016 but will partially recover by 2023, says research and consulting firm GlobalData.

The company estimates that sales will fall from $2.1 billion in 2013 to $1.4 billion by 2016, before steadily recovering to $1.8 billion by 2023. The launch of Merck & Co’s (NYSE: MRK) Belsomra (suvorexant) and Eisai’s (TYO: 4523) E-2006 will drive this stabilization, as well as an increase in prevalent cases of insomnia.

The sharp sales decline is set to hit seven major markets: the USA, France, Germany, Italy, Spain, the UK and Japan, and will be primarily due to the generic erosion of Lunesta (eszopiclone) in the USA, manufactured by Sunovion/Dainippon Sumitomo (TYO: 4506). Lunesta was the highest selling treatment in 2013, with sales of around $617.9 million, but Belsomra is expected to be the market leader by 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >